Weizhen Sun

Weizhen Sun

Personal Introduction

He holds a PhD in Chemical and Biological Engineering from the University of Sheffield, where his research sat at the intersection of physics, chemistry, and engineering for biomedical applications. He published five first-author SCI papers during his doctoral studies, including contributions to Advances in Colloid and Interface Science and the Journal of Colloid and Interface Science, one of which was recognised as an ESI Highly Cited Paper. After graduation, he joined Nanjing Auro Biotechnology (part of Grand Pharmaceutical Group) as a Formulation Scientist, contributing to the localisation of several international licence-in projects, including the development of an mRNA drug platform and an HPV16 mRNA vaccine programme that progressed from bench and pilot studies through to a successful IND submission. He also led an LNP surface modification project that secured over RMB 2 million in joint funding from Grand Pharma and the Nanjing Municipal Government. He is currently a Microfluidics Project Researcher at the Cambridge University Nanjing Centre for Technology and Innovation, working on the application development, translation, and commercialization of microfluidic technologies.

 

 

 

Ph.D., Department of Chemical and Biological Engineering, University of Sheffield